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Insulin-like growth factor I (IGF-I) stimulates an in-
crease in V3 ligand binding. Stimulation of smooth
muscle cells by IGF-I requires V3 ligand occupancy,
and enhanced V3 ligand occupancy augments IGF-I
actions. Therefore, IGF-I-induced changes in V3 li-
gand binding may act to further enhance IGF-I actions.
Integrin-associated protein (IAP) has been shown to be
associated with V3 and is required for the binding of
V3 to vitronectin-coated beads. We therefore investi-
gated whether IGF-I could stimulate IAP-V3 associa-
tion resulting in enhanced ligand binding. IGF-I stimu-
lated an increase in IAP-V3 association. This was due,
at least in part, to an IGF-I-stimulated redistribution of
IAP from the Triton-insoluble fraction of the cell to the
Triton-soluble fraction of the cell, where most of the
V3 was located. Inhibition of the phosphatidylinositol
3-kinase pathway blocked both the redistribution of IAP
and the increase in IAP-V3 association, providing fur-
ther evidence that the redistribution of IAP is essential
for the increase in association. An anti-IAP monoclonal
antibody, blocked both the IGF-I-stimulated increase in
IAP-V3 complex formation and cell migration. IGF-I-
stimulated translocation of IAP and increase in IAP-
V3 association represent an important process by
which IGF-I modulates V3 ligand binding and cellular
responses.
Insulin-like growth factor I (IGF-I)1 is a potent stimulant of
vascular smooth muscle cell migration (1–3). The V3 integrin
is an important cellular membrane receptor that is utilized by
IGF-I to regulate vascular smooth muscle cell migration. Spe-
cific inhibitors of V3 ligand occupancy block IGF-I-stimulated
migration (4). Additionally, treatment of cells with IGF-I has
been shown to increase ligand binding by V3 (5). This IGF-
I-induced change in V3 affinity may be an important compo-
nent of its ability to stimulate cell migration. The mechanism
by which IGF-I stimulates the increase in ligand binding is
unknown. IGF-I does not physically associate with V3 (6),
which suggests that IGF-I may be acting via an intermediary
protein to exert its effects on V3 affinity.
Signals from within the cell can result in changes in integrin
ligand affinity and avidity. One of the proteins implicated in
these events is integrin-associated protein (IAP), also termed
CD47. IAP was first identified due to its association with V3
purified from placenta (7). IAP is expressed on many mamma-
lian cells and consists of a N-terminal (extracellular) immuno-
globulin variable (IgV)-type domain followed by five potential
membrane-spanning hydrophobic helices and a cytoplasmic
tail (8, 9). Its involvement in integrin signaling is suggested
both by its physical association with integrins (7) and by ex-
perimental results showing that antibodies to IAP affect a large
number of functions associated with V3 (9, 10). More specif-
ically, anti-IAP antibodies inhibit the binding of V3 in a
variety of cells lines (11) to vitronectin (Vn)-coated beads. Fur-
thermore, it has been shown that the IAP-negative cell line
OV10 (an ovarian carcinoma cell line) can only bind Vn-coated
beads if these cells are made to express IAP (12).
Because IGF-I exposure enhances ligand binding to V3, we
determined whether IGF-I receptor activation altered the
physical association of IAP with V3 and thereby increased its
ability to bind to ligands and whether inhibition of IAP-V3
association resulted in inhibition of IGF-I-stimulated cell mi-
gration. To investigate the mechanism by which IGF-I stimu-
lated IAP-V3 association, we determined whether V3 and
IAP were associated with different lipid compartments of the
cellular membrane and whether IGF-I could alter this distri-
bution, thus allowing better access of IAP to V3.
EXPERIMENTAL PROCEDURES
Materials—Human IGF-I was a gift from Genentech (South San
Francisco, CA). Polyvinylidene difluoride filters were purchased from
Millipore Corp. (Bedford, MA). Autoradiographic film was obtained
from Eastman Kodak Co. Fetal bovine serum, Dulbecco’s modified
Eagle’s medium, penicillin, and streptomycin were purchased from
Invitrogen. Polyclonal anti-V and anti-3 antisera were purchased
from Chemicon (Temecula, CA). The monoclonal antibody used to detect
IAP (B6H12) was a kind gift from Dr. Eric Brown (Washington Univer-
sity, St Louis, MO). Polyclonal antibody against IAP was raised in
rabbit against amino acids 50–70 of the human IAP extracellular do-
main. The polyclonal antibody against 3 was raised in rabbit against
amino acids 60–85 of the porcine 3 sequence. Biotinylated human Vn
was a kind gift from Wayne Engleman (Amersham Biosciences, Inc.).
All other reagents were purchased from Sigma Chemical Co. unless
otherwise stated.
Porcine aortic smooth muscle cells (pSMCs) were isolated as de-
scribed previously (13) and maintained in Dulbecco’s modified Eagle’s
medium supplemented with glucose (4.5 g/liter), penicillin (100 units/
ml), streptomycin (100 ng/ml), and 10% fetal bovine serum in 10-cm
tissue culture plates. The cells were used between passage 5 and 16.
Determination of Soluble Vn Binding to V3—Cells were grown to
80% confluence in 48-well plates. The cells were then incubated over-
night in serum-free Dulbecco’s modified Eagle’s medium H plus 0.01%
bovine serum albumin (SFM) and then exposed to 100 ng/ml IGF-I for
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the appropriate length of time. The cells were then washed three times
with SFM plus 20 mM HEPES and incubated with biotinylated Vn (108
M) in SFM containing 20 mM HEPES for 5 h at 4 °C. The cells were
rinsed again in SFM before lysis at 4 °C in ice-cold buffer A (150 mM
HEPES, pH 7.5, 50 mM NaCl, 1% Nonidet P-40, 1 mM sodium or-
thovanadate, 1 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluo-
ride, 1 g/ml pepstatin A, 1 g/ml leupeptin, and 1 g/ml aprotinin).
The lysates were clarified by centrifugation at 14,000  g for 10 min at
4 °C. Equal amounts of protein were then separated under nonreducing
conditions by SDS-PAGE, 8% gel. The amount of biotinylated vitronec-
tin in each sample was visualized as described below.
Preparation of Whole Cell Lysates—Cells were incubated overnight
in SFM and then exposed to 100 ng/ml IGF-I as indicated in each figure.
Cells were then rinsed three times with phosphate-buffered saline (pH
7.4) and lysed by the addition of 900 l of boiling 2 Laemmli buffer.
Cell lysates were scraped from the dish into microcentrifuge tubes and
boiled for 5 min. To reduce viscosity, samples were then sonicated for
10 s and centrifuged again for 5 min. Lysates were then separated
under nonreducing conditions by SDS-PAGE, 8% gel. The level of each
protein was then determined by Western immunoblotting as described
below.
Determination of IAP-integrin Association—Cells were incubated
overnight in SFM and then exposed to 100 ng/ml IGF-I for the appro-
priate length of time before lysis at 4 °C in ice-cold 0.2% Triton X-100
lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM sodium
orthovanadate, 1 mM sodium fluoride, 1 mM phenylmethylsulfonyl flu-
oride, 1 g/ml pepstatin A, 1 g/ml leupeptin, and 1 g/ml aprotinin
(buffer B)). The lysates were clarified by centrifugation at 14,000  g for
10 min 4 °C. In some experiments, cells were preincubated with 4 g/ml
B6H12 (an anti-IAP monoclonal antibody) before the addition of IGF-I.
Immunoprecipitation was then carried out as described below.
Determination of the Distribution of Proteins between the Triton-
soluble and -insoluble Fractions—Cells were incubated in SFM and
then exposed to 100 ng/ml IGF-I for the appropriate length of time
before lysis at 4 °C in buffer B. The lysates were clarified by centrifu-
gation at 14,000  g for 10 min at 4 °C. The resultant supernatant was
termed the Triton-soluble fraction. The remaining pellet was resus-
pended in lysis buffer C (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1%
Nonidet P-40, 0.25% sodium deoxycholate, 1 mM EGTA, 1 mM sodium
orthovanadate, 1 mM sodium fluoride, 1 mM phenylmethylsulfonyl flu-
oride, 1 g/ml pepstatin A, 1 g/ml leupeptin, and 1 g/ml aprotinin).
The resuspended pellet was re-centrifuged at 14,000  g for an addi-
tional 10 min at 4 °C, and the resulting supernatant was considered to
be the Triton-insoluble fraction of the cell, excluding the insoluble
cytoskeletal fraction. This method has been shown to separate proteins
that are bound to membrane rafts (Triton-insoluble) from those that are
not raft-associated (Triton-soluble), as verified by sucrose gradient den-
sity centrifugation (14–16). 10 l of 4 nonreducing Laemmli buffer
was added to 50 l of each supernatant and heated at 65 °C for 10 min.
The proteins were separated by SDS-PAGE (8% gel) and then visual-
ized by Western immunoblotting as described below.
To test the effect of the various inhibitors on IGF-I-stimulated IAP-
integrin association and IGF-I-stimulated redistribution of IAP, follow-
ing overnight incubation in SFM, the cells were incubated with either
0.1% DMSO (vehicle) or the appropriate inhibitor (100 nM wortmannin
or 1 M Ly294002) for 30 min before the addition of IGF-I. We have
previously shown that wortmannin and Ly294002 at these concentra-
tions specifically inhibit different physiological actions of IGF-I and
that their inhibitory activity can be maintained for at least 24 h (18).
Immunoprecipitation—The supernatants were incubated overnight
at 4 °C with the appropriate antibody (polyclonal anti-V antibody at
1:1000, polyclonal anti-3 antibody at 1:1000, or monoclonal anti-IAP
antibody (B6H12) at 1:500). Immune complexes were then precipitated
by the addition of protein A-Sepharose and incubation for an additional
2 h at 4 °C. The samples were then centrifuged at 14,000  g for 10 min,
and the pellets were washed four times with lysis buffer. The pellet was
suspended in 45 l of nonreducing Laemmli buffer and heated at 65 °C
for 10 min, and the proteins were separated by SDS-PAGE, 8% gel.
Western Immunoblotting—After SDS-PAGE, the proteins were
transferred to a polyvinylidene difluoride membrane. The membranes
were blocked in 1% bovine serum albumin in Tris-buffered saline with
0.1% Tween (TBST) for 2 h at room temperature. The membranes were
incubated with one of four primary antibodies (the IAP monoclonal
antibody (B6H12) at 1:500, the IAP polyclonal antibody at 1:500, the 3
polyclonal antibody at 1:500, or the V polyclonal antibody at 1:500)
overnight at 4 °C and then washed three times in TBST before incuba-
tion with the appropriate horseradish peroxidase-conjugated secondary
antibody. To visualize the biotinylated vitronectin, membranes were
incubated with extravidin conjugated to horseradish peroxidase (1:
10,000). Binding of the peroxidase-labeled antibody was visualized us-
ing enhanced chemiluminescence following the manufacturer’s instruc-
tions (Pierce).
Cell Wounding and Migration Assay—Cells were plated in 6-well
plates and grown to confluence over a 7-day period with one media
change. Wounding was performed as described previously (5). Briefly, a
razor blade was used to scrape an area of cells, leaving a denuded area
and a sharp visible wound line. The wounded monolayers were then
rinsed three times in SFM, and then ten 1-mm areas along the wound
edge were selected and recorded for each treatment. The wounded
monolayers were then incubated with SFM (plus 2% fetal bovine serum)
with or without 100 ng/ml IGF-I. To test the effect of B6H12 on IGF-I-
stimulated migration, the wounded monolayers were incubated with
B6H12 (4 g/ml) for 2 h before the addition of IGF-I. The cells were then
fixed and stained (Diff Quick; Dade Behring, Inc., Newark, DE), and the
number of cells migrating into the wound area was counted. At least
five of the previously selected 1-mm areas at the edge of the wound were
counted for each data point.
Our previous analysis of the wounded monolayer by [3H]thymidine
autoradiography demonstrated that the labeling index of pSMCs at the
wounded edge was 7  4% at the basal level and 18  7% after
treatment with IGF-I. Therefore, 10% of cells present in the denuded
area at the end of the migration assay are considered to result from cell
division rather than cell migration (5).
Student’s t test was used to compare differences between treatments.
Band intensities on autoradiographs were measured by scanning den-
sitometry and analyzed using NIH Image, version 1.61. The results
shown are representative of at least three similar experiments.
RESULTS
IGF-I Stimulates an Increase in the Binding of Soluble Vn to
the V3 Integrin—A 24-h incubation with IGF-I followed by
measurement of biotinylated Vn binding to the cell surface
showed that binding was significantly increased (6.1  1.4-fold,
mean  S.E.; n  3; p  0.05). This effect required at least 12 h
of incubation because no increase was observed at earlier time
points. A representative experiment is shown in Fig. 1A. There
was no significant change in the level of either V (Fig. 1B) or
3 (Fig. 1C) during the time course of this experiment, and this
confirms our previous observation that there was no increase in
V3 receptor number in response to IGF-I (5). This suggests
that the increase in V3 ligand binding that occurs after IGF-I
receptor stimulation is not simply due to an increase in integrin
receptor number and is probably due to a change in the affinity
of V3 for vitronectin. The IGF-I receptor does not physically
associate with the V3 integrin (6), which suggests that IGF-I
exerts its effects on integrin ligand binding via an intermediary
protein.
IGF-I Stimulates an Increase in the Association of IAP with
V3 Integrin—Previous reports have suggested that the direct
physical association of the extracellular domain of IAP with the
FIG. 1. A, IGF-I stimulates an increase in Vn binding to V3. Cells
were grown to 80% confluence and incubated with IGF-I for 6, 12, or
24 h. This was followed by a 5-h incubation with 108 M biotinylated
vitronectin. After lysis, the amount of biotinylated vitronectin associ-
ated with the cells was determined by Western immunoblotting. The
results are expressed as arbitrary scanning units: lane 1, 4315; lane 2,
4857; lane 3, 16,706; and lane 4, 18,451. B and C, IGF-I does not
increase the amount of V or 3. Cell lysates from cells incubated with
or without IGF-I were immunoblotted with an anti-V (B) or anti-3 (C)
antibody.
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V3 integrin is necessary and sufficient for V3 binding to
Vn-coated beads (12). Because both IAP and V3 are ex-
pressed on the cell surface, we investigated whether treatment
of pSMCs with IGF-I increased the physical association of IAP
with V3, thus contributing to the enhancing effect of IGF-I on
V3 ligand affinity. We have shown previously that the ma-
jority of V on the surface of pSMCs is associated with 3 (5); we
therefore used an antibody against the V subunit to immuno-
precipitate the V3 integrin receptor and then immunoblotted
for IAP to examine changes in complex formation. Fig. 2A
shows that in pSMCs, minimal IAP was associated with the
V3 integrin in the basal state. In contrast, after a 12-h
incubation with IGF-I, there was a 6-fold increase in IAP-V3
association, and this increased still further after a 24-h incu-
bation with IGF-I (6.5  1.75-fold, mean  S.E.; n  3; p 
0.05). Importantly no increase in IAP-V3 association was
detected at the earlier 6 h time point. This time course is the
same as that observed for the increase in vitronectin binding
shown in Fig. 1. Because IAP forms a complex with the V3
dimer but not with either subunit alone, to control for loading
differences we immunoblotted for 3 because this would be
precipitated with the V, and we therefore believe it is a better
index of the total amount of V3 that was immunoprecipitated
in each lane. Immunoblotting for 3 shows that there was no
change in the amount of V3 immunoprecipitated between the
different treatments that would account for the increase in IAP
(Fig. 2B). Fig. 2C shows that there was no increase in the total
cellular content of IAP during the time course of the
experiment.
IGF-I Stimulates the Redistribution of IAP from the Triton-
insoluble to the Triton-soluble Fraction of the Cell—It has been
shown previously that increasing the expression of IAP or V3
can increase complex formation (12). However, as shown in
Figs. 1 and 2, there were no changes in the total amount of V,
3, or IAP during the time course of the experiment. It is known
that plasma membrane proteins can be associated with differ-
ent microdomains of the membrane, based upon the polarity of
the lipid groups (14). Sucrose gradient density centrifugation
has been used to separate membrane raft proteins from pro-
teins associated with non-raft domains (14). Extraction of these
membrane subfractions with Triton at 4 °C has shown that the
Triton-insoluble fraction corresponds to proteins associated
with membrane rafts as determined by sucrose gradient den-
sity centrifugation (14–16). IAP-V3 complex formation can
only be detected after lysis in a Triton buffer, which suggested
that the increase in their association might be due to a specific
increase in the levels of one or both of the complex components
in the Triton-soluble fraction. We therefore investigated the
distribution of complex components between the Triton-soluble
and Triton-insoluble fractions of the cell before and after IGF-I
stimulation following protein extraction at 4 °C. To first con-
firm that proteins from the Triton-insoluble fraction had been
separated from proteins from the Triton-soluble fraction, we
immunoblotted for caveolin, a protein known to be associated
almost exclusively with membrane rafts (17) and therefore
found in the Triton-insoluble fraction of the plasma membrane.
Fig. 3A confirms that 82  6.5% (mean  S.E.; n  3) of
caveolin was detected in the Triton-insoluble fraction. In Fig.
3B, it can be seen that the majority of V (top panel; 94  6%,
mean  S.E.; n  3) and 3 (bottom panel; 93  7%, mean 
S.E.; n  3) was associated with the Triton-soluble fraction of
the cell, and there was no significant change in V3 distribu-
tion after IGF-I treatment. In contrast, Fig. 3C shows that in
the basal state, 85  7.7% (mean  S.E.; n  3) of the total IAP
was associated with the Triton-insoluble membrane fraction.
Importantly, after incubation with IGF-I, there was a marked
decrease (2.2-fold) in the amount of IAP in the Triton-insoluble
fraction and an increase (3-fold) in IAP in the Triton-soluble
fraction. After treatment with IGF-I, 79.7  10.5% (mean 
S.E.; n  3) of the total IAP was associated with the Triton-
soluble fraction.
Inhibition of the PI3K Pathway Inhibits the IGF-I-stimulated
Increase in IAP-Integrin Association—To provide further evi-
dence that the IGF-I-stimulated redistribution of IAP is impor-
FIG. 2. IGF-I stimulates an increase in IAP-V3 association. A,
cells were grown to 80–90% confluence in 10-cm plastic dishes in
growth medium and then incubated overnight in SFM. This was fol-
lowed by a 6-, 12-, or 24-h incubation with or without IGF-I (100 ng/ml).
After lysis and immunoprecipitation with an anti-V antibody, the level
of IAP association was determined by Western immunoblotting with
the anti-IAP monoclonal antibody. The results are expressed as arbi-
trary scanning units: lane 1, 3741; lane 2, 3954; lane 3, 22,754; and lane
4, 26,027. B, the amount of V3 immunoprecipitated before and after
24-h treatment with IGF-I in the same experiment was determined by
stripping the blot and reprobing with an anti-3 polyclonal antibody.
The results are expressed as arbitrary scanning units: lane 1, 25,472;
and lane 2, 23,210. C, the level of IAP in whole cell lysates before and
after 24-h treatment with IGF-I was determined by immunoblotting
with the anti-IAP monoclonal antibody. The results are expressed as
arbitrary scanning units: lane 1, 52,866; and lane 2, 42,538.
FIG. 3. IGF-I stimulates the redistribution of IAP from the
Triton-insoluble fraction to the Triton-soluble fraction of the
cell. A–C, after overnight incubation in SFM, cells were incubated in
either SFM or IGF-I for the indicated length of time; Triton-soluble and
Triton-insoluble cell lysates were either separated immediately by SDS-
PAGE (A and B) or first immunoprecipitated with an IAP monoclonal
antibody (B6H12) (C). Proteins were visualized after incubation with
the indicated antibody. The results in C are expressed as arbitrary
scanning units: lane 1, 8392; lane 2, 6136; lane 3, 3731; lane 4, 2141;
lane 5, 5384; and lane 6, 6475.
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tant for the increase in complex formation, we examined the
effect of various inhibitors on both IGF-I-stimulated IAP redis-
tribution and IAP-integrin complex formation. We have previ-
ously shown that inhibitors of the PI3K pathway effectively
block IGF-I-stimulated migration (18). Fig. 4A shows, as be-
fore, that IGF-I stimulates a 1.7-fold decrease in IAP levels in
the Triton-insoluble fraction (top panel) and a 2.2-fold increase
in the Triton-soluble fraction (bottom panel). However, in the
presence of two structurally distinct PI3K inhibitors, wortman-
nin and LY294002, the IGF-I-stimulated redistribution of IAP
from the Triton-insoluble fraction to the Triton-soluble fraction
was inhibited. This inhibition of IAP translocation from the
Triton-insoluble fraction to the Triton-soluble fraction was as-
sociated with an inhibition in IGF-I-stimulated complex forma-
tion (Fig. 4B, top panel). Reprobing of the membrane with the
3 antibody (Fig. 4B, bottom panel) showed that the reduction
in IAP-V3 association was not due to changes in the amount
of V3 immunoprecipitated under each condition. Neither of
the inhibitors had any effect on basal IAP-integrin association
(data not shown).
B6H12, the Anti-IAP Monoclonal Antibody, Blocks Both IGF-
I-stimulated IAP-Integrin Complex Formation and Cell Migra-
tion—To determine whether the IGF-I-stimulated increase in
IAP binding to V3 was required for IGF-I-stimulated migra-
tion, we determined the effect of inhibiting complex formation
on this process. Fig. 5A (top panel) shows that the monoclonal
anti-IAP antibody (B6H12) potently inhibited the IGF-I-stim-
ulated increase in IAP-integrin complex formation. Reprobing
of the membrane with the 3 antibody (Fig. 5A, bottom panel)
showed that the reduction in association was not due to
changes in the amount of V3 immunoprecipitated under each
condition. Fig. 5B shows that although IGF-I stimulated a
significant (3.3  0.1-fold, mean  S.E.; n  3; p  0.05)
increase in cell migration, this increase was completely inhib-
ited if cells were preincubated with B6H12.
DISCUSSION
Similar to some types of transmembrane receptors, integrins
have the ability to modulate their affinity for extracellular
ligands in response to various signals from within the cell. This
change can result in a switch from an inactive to an activated
state (22). Binding of the activated integrin to extracellular
proteins then generates signals that regulate cell adhesion,
spreading, and migration. Several studies have shown that IAP
can modulate V3 affinity for its ligand, Vn. Using both anti-
IAP antibodies and IAP-negative cells, it has been shown that
IAP is required for V3 binding to Vn-coated beads (11, 12).
Membrane-anchored IAP containing one IgG domain in the
extracellular region of the molecule is required to detect a
positive effect of IAP on integrin signaling (12). This suggests
that a direct physical association between the extracellular
domain of IAP and the extracellular regions of V and/or 3
occurs. In previous studies, we have shown that IGF-I can
FIG. 4. A, effect of PI3K inhibitors on IGF-I-stimulated redistribution
of IAP. Cells were incubated overnight in SFM, and the inhibitors (100
nM wortmannin or 1 M Ly294002) were added 30 min before the
addition of IGF-I. After a 24-h incubation, the Triton-soluble and Tri-
ton-insoluble cell lysates were immunoprecipitated with the anti-IAP
monoclonal antibody (B6H12). The level of IAP was then determined by
Western immunoblotting with the polyclonal anti-IAP antibody. The
results are expressed as arbitrary scanning units. Top panel: lane 1,
19,231; lane 2, 11,105; lane 3, 19,765; and lane 4, 16,882. Bottom panel:
lane 1, 14,365; lane 2, 32,108; lane 3, 17,508; and lane 4, 11,964. B,
effect of PI3K inhibitors on IGF-I-stimulated increase in IAP-V3
association. Cells were incubated overnight in SFM, and the inhibitors
(100 nM wortmannin or 1 M Ly294002) were added 30 min before the
addition of IGF-I. After a 24-h incubation, cell lysates were then im-
munoprecipitated with V, and the amount of IAP associated with the
V3 complex was determined by immunoblotting with the anti-IAP
monoclonal antibody (top panel). The results are expressed as arbitrary
scanning units: lane 1, 2797; lane 2, 28,643; lane 3, 2396; and lane 4,
1635. To control for loading inequities, the amount of V3 immunopre-
cipitated in the same experiment is shown in the bottom panel by
immunoblotting for 3. The results are expressed as arbitrary scanning
units: lane 1, 1811; lane 2, 1545; lane 3, 2282; and lane 4, 1442.
FIG. 5. A, effect of anti-IAP monoclonal antibody B6H12 on the IGF-
I-stimulated increase in IAP-V3 complex formation. Cells were grown
to 80–90% confluence in 10-cm plastic dishes in growth medium and
then incubated overnight in SFM. This was followed by a 2-h incubation
with or without B6H12 (4 g/ml). This was then followed by a 24-h
incubation with or without IGF-I. After lysis and immunoprecipitation
with an anti-V antibody, the level of IAP association was determined
by Western immunoblotting with the monoclonal anti-IAP antibody (top
panel). The results are expressed as arbitrary scanning units: lane 1,
4907; lane 2, 13,471; lane 3, 6590; and lane 4, 4164. To control for
loading inequities, the amount of 3 co-precipitating with V in the
same experiment is shown in the bottom panel. The results are ex-
pressed as arbitrary scanning units: lane 1, 4818; lane 2, 5295; lane 3,
5482; and lane 4, 6286. B, effect of anti-IAP monoclonal antibody B6H12
on IGF-I-stimulated migration. Cells were grown to confluence over a
7-day period and then wounded as described under “Experimental
Procedures.” Cells were preincubated with B6H12 (4 g/ml) for 2 h
before the addition of IGF-I (100 ng/ml). The number of cells migrating
across the wound at at least five preselected regions of the wound was
counted. Each data point represents the mean  S.E. of three independ-
ent experiments. , p  0.05 when migration in the presence of IGF-I
is compared with incubation in SFM alone.
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stimulate a significant increase (2.4-fold) in V3 ligand bind-
ing to the disintegrin kistrin and that this change requires
12 h. In this study, we have extended that observation to show
that IGF-I can stimulate a 7-fold increase in the binding of
V3 to soluble Vn and that this increase requires at least 12 h
of incubation with IGF-I. The results from this study show that
IGF-I stimulates a 6.5-fold increase in IAP association with
V3 over the same time course. In light of the clearly estab-
lished role of IAP in modulating the binding of Vn to V3 and
the similar time course, we propose a model whereby IGF-I
stimulates this increase in ligand binding by stimulating the
physical association of IAP and V3.
Both IAP and V3 have been shown to be expressed on the
cell surface independently of each other, and complex forma-
tion is believed to be in equilibrium with nonassociated IAP
and V3 (12). A previous study showed that increasing the
level of expression of either V3 or IAP in the Triton-soluble
fraction led to increased complex formation and increased
vitronectin-coated bead binding (12). Our results show that
IGF-I treatment stimulates this increase in IAP-V3 associa-
tion, at least in part, by stimulating the redistribution of IAP
from the Triton-insoluble fraction to the Triton-soluble frac-
tion, the fraction with which 90% of the V3 is associated.
Our conclusion that the increase in IAP association with
V3 requires translocation of IAP to the Triton-soluble frac-
tion is supported by our findings using the inhibitors of PI3K.
Blocking the PI3K pathway inhibited both redistribution of
IAP to the Triton-soluble fraction and IAP-V3 complex for-
mation. Because we have shown that inhibiting PI3K inhibits
the cellular migration response to IGF-I (18), these results
support the conclusion that redistribution of IAP is required for
IGF-I-stimulated increase in IAP-V3 association and that
this change could lead to stimulation of cell migration. It re-
mains to be determined whether this is only one of several
steps required for IGF-I to increase IAP-V3 association or
whether this is the only change required. Because both IAP and
V3 undergo conformational changes (19), these changes could
also be necessary for the observed increase in complex forma-
tion to occur.
Previous studies have suggested that the cellular localiza-
tion of IAP may be important in the regulation of its activity
(20, 21). Plasma membranes contain specialized glycosphingo-
lipids and cholesterol-rich domains (membrane rafts) that have
been proposed to be regulators of cell surface signal transduc-
tion via the segregation of membrane constituents. The pro-
teins associated with membrane rafts can be isolated because
of their resistance to solubilization by nonionic detergents at
4 °C (14). It has been suggested that membrane rafts are effi-
cient sites for the initiation of signal transduction due to the
sequestration of specific components of signaling complexes
within this membrane fraction. However, in some cases, sig-
naling molecules are also translocated out of rafts. Previous
studies have demonstrated that IAP is associated predomi-
nantly but not exclusively with membrane rafts (20, 21). It was
shown in C32 melanoma cells that V3 within the membrane
raft was four times more likely to form a complex with IAP
compared with V3 in the Triton-soluble component and that
cholesterol, which is necessary for stabilization of raft forma-
tion, is also required for complex assembly and signaling (20).
In a different context, e.g. T-cell signaling, the association of
IAP with membrane rafts was associated with its ability to
stimulate an increase in f-actin-stimulated cell spreading and
the association of protein kinase C with the cytoskeleton (21).
However, it was also shown in the C32 melanoma cells that IAP
in the Triton-soluble fraction formed a complex with 3 and G
proteins and that association with membrane rafts was not
necessary for the IAP enhancement of V integrin binding to
Vn-coated beads (12). Similarly, in T cells, IAP participation in
phospholipase C and Ca2 signaling was not dependent on its
raft association (21). Thus, these studies have demonstrated
that IAP is capable of interacting with both integrins and
signaling cascades both within and outside of membrane rafts.
Because insolubility in Triton detergent at 4 °C is a character-
istic of proteins associated with membrane rafts (14), and given
that caveolin, a marker protein for membrane rafts (17), was
also found almost exclusively in the Triton-insoluble fraction, it
seems likely that in our experiments extraction with Triton at
4 °C accurately reflected both IAP and caveolin associated with
membrane rafts. Because V3 was associated almost exclu-
sively with the Triton-soluble fraction, consistent with previous
reports (23), and complex formation only occurred after redis-
tribution of IAP into the Triton-soluble fraction, our studies
suggest that the site of localization of both V3 and IAP
appears to be a major determinant of whether they will
interact.
To our knowledge, this is the first report describing the
stimulation of translocation of IAP from the Triton-insoluble to
the Triton-soluble fraction, and it suggests that IGF-I may be
an important regulator of IAP activity through its ability to
regulate its cellular distribution. Exactly how IGF-I stimulates
this redistribution remains to be elucidated. Possible mecha-
nisms include the alteration of an abundant raft protein such
as caveolin-1 or changes in potential posttranslational modifi-
cations within IAP that have been shown to account for raft
association such as glycosylphosphatidyl inositol anchoring,
palmitylation, or myristylation (14).
In the absence of appropriate cells that do not express IAP,
we cannot say definitively that the IGF-I-stimulated increase
in IAP association with V3 results in the increase in ligand
binding. However, previous studies demonstrating such a role
for IAP strongly support this interpretation. However, our
study does show that IAP plays an important role in IGF-I-
stimulated vascular smooth muscle cell migration because the
anti-IAP monoclonal antibody can block both the IGF-I-stimu-
lated increase in IAP association with V3 and IGF-I-stimu-
lated migration. This is consistent with a previous report that
demonstrated that an IAP-integrin association was involved in
stimulation of vascular smooth muscle cell migration in re-
sponse to thrombospondin-1 (24). However, in that study, the
integrin involved was 21; because our cells express very low
levels of 21 (5), we cannot determine whether IGF-I can have
a similar effect on IAP association with this integrin. Despite
the differences in integrin expression, both studies suggest that
the IAP regulation of integrin ligand binding is an important
mechanism in the regulation of smooth muscle cell migration in
response to different stimuli. Additional studies will be neces-
sary to elucidate whether the IAP also has additional signaling
effects contributing to IGF-I-stimulated migration independent
of its effect on V3.
In summary, we have shown that IGF-I can stimulate an
increase in IAP-integrin association via a PI3K-dependent
pathway. This increase appears to result from an increase in
IAP association with the Triton-soluble fraction of the cell.
Taken together with previous evidence showing that IAP can
increase V3 binding to Vn, the data presented here suggest
that the IGF-I regulation of IAP cellular distribution may be
involved in the ability of IGF-I to alter the ligand binding
capacity of V3. Because ligand binding by integrins triggers
signals inside the cell necessary for cell migration, our findings
suggest that the IAP-induced alteration in V3 ligand binding
is important in the regulation of IGF-I-stimulated cell
migration.
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